Bayer, Nuvisan to open small molecule research center

By Jenni Spinner

- Last updated on GMT

(Image: Getty/Gorodenkoff)
(Image: Getty/Gorodenkoff)

Related tags: Bayer, Nuvisan, Germany

The firms are joining forces to establish a specialized research unit in Berlin.

Bayer plans to shift a significant portion of its Berlin-based small molecule research activity to Nuvisan. The latter company provides clinical study, laboratory and contract manufacturing services.

Joerg Moeller, head of research and development for Bayer AG’s Pharmaceuticals Division and member of its executive committee, said the firm hopes to build a “strong, full-fledged research unit​” with Nuvisan.

Nuvisan shares our vision that the new research center can become an important player in research partnering based on the joint know-how and capabilities of our highly qualified scientists​,” Moeller said.

The new research entity housed at the center reportedly will create 400 jobs in the area. Capabilities across the drug discovery chain include lead discovery, medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics, investigational toxicology, and animal management.

Dietrich Bruchmann, Nuvisan CEO and managing partner, said the capabilities of the German facility will empower a “high-performance research team​” by offering access to specialized technology.

The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster in Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials​,” Bruchmann said.

According to Bayer, the partnership will enable the company to focus its efforts on R&D flexibility and productivity. Bayer intends to continue additional research activities and corporate functions at its Berlin-based Pharmaceuticals Division.

The arrangement marks the latest in a series of partnerships Bayer has formed with other entities in the past few months. In late January 2020, the firm inked a five-year deal with Schrodinger​ to develop molecule-design software. A few weeks earlier, Bayer expanded its work with Evotec​ on developing women’s health drugs.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars